Weekly updates on the most current research in breast cancer. Will follow all cancer researchers back. Here to make research more available to everyone.
Joined October 2020
- Tweets747
- Following1.2K
- Followers1.2K
- Likes999
Pinned Tweet
If you are a young breast cancer researcher who would like to be featured on our wall please send a DM 🩺
#breastcancer #youngresearchers #youngoncologists #research #cancer #oncology #epitwitter #phdchat #PhD #cancerresearch #younginvestigator #globaloncology
Breast Cancer Research Updates retweeted
Top #ASCO24 picks in breast #bcsm oncology!
Exciting! Next week!
@OncoAlert
@SarahCannonDocs
@myESMO
Dear Colleagues,
The @OncoAlert 🚨Network Presents OUR Picks of
TOP 🔟Abstracts to be Presented at #ASCO24
This List Curated by:
#OncoAlertAF Leads : @ElisaAgostinett 🇧🇪 @to_be_elizabeth 🇮🇹 @weoncologists 🇺🇸
With our distinguished OncoAlert Faculty:
@ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @E_de_Azambuja 🇧🇪 @hoperugo 🇺🇸 @stolaney1 🇮🇹 @matteolambe 🇮🇹 and @JaniceTNBCmets 🇮🇹
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy : Primary results from DESTINY-Breast06 (DB-06).
meetings.asco.org/abstracts-…
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.
meetings.asco.org/abstracts-…
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.
meetings.asco.org/abstracts-…
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial
meetings.asco.org/abstracts-…
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL
meetings.asco.org/abstracts-…
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
meetings.asco.org/abstracts-…
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
meetings.asco.org/abstracts-…
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
meetings.asco.org/abstracts-…
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.
meetings.asco.org/abstracts-…
On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).
meetings.asco.org/abstracts-…
@aftimosp @NicoleKuderer @FAndreMD @prat_aleix @jesusanampa @StoverLab @curijoey @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @raalbany @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD
@paspears88 @MammaMiaMagazin
#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@dr_yakupergun @anmwongNZ
Breast Cancer Research Updates retweeted
#ESMOBreast24 #ESMOAmbassadors
🔑🚫Primary outcome in IMpassion132 highlights unmet need for early relapsing #TNBC
🔑Emerging data from ADC-IO combinations
🔑Safety and #QoL updates for new 💊capivasertib and 💉datopotamab
🔑📈Body of evidence for new biomarkers 🎯such as HER2Dx
#ESMOBreast24: What do you find the most relevant #ScientificAdvancements in #OncologyResearch? Share the newest findings that you consider having the potential to improve #CancerCare in #bcsm. #BreastCancer #ESMOAmbassadors
Breast Cancer Research Updates retweeted
A very interesting review🙌🏻😱 on the complex relationship between diabetes and breast cancer raises crucial considerations in treatment decisions, especially in women with comorbidities. The review 🕵🏻highlights the undeniable connection between diabetes and an increased risk of developing breast cancer, underlining the importance of careful management of anti-diabetic therapy.
🟩The promising effects observed in new antidiabetic drugs are explored, suggesting potential benefits in reducing cancer risk. The research also hints at the relevance of reconsidering current recommendations for the pharmacological prevention of breast cancer, especially in individuals with overweight or type 2 diabetes.
🟦Precise management of therapies such as insulin, metformin, and SGLT-2 inhibitors emerges as a determining factor that could positively impact prognosis. These new anti-diabetic drugs generate hope by offering innovative strategies for cancer risk reduction.
🟧Taken together, it is suggested that comprehensive diabetes management in breast cancer patients may have a significant impact on prognosis. 💡The possibility of adjusting pharmacological preventive strategies is proposed as a way to optimize outcomes in patients with these concomitant conditions. @OncoReporte @VukovicPetra @Dr_RShatsky @AnaVManana
mdpi.com/2072-6694/16/2/299
Breast Cancer Research Updates retweeted
📈 Highly cited paper (2022): "Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice" by Dr. @SeanHacking and Dr. Yihong Wang (@BrownPathRes @BrownPathology).
🔗 Read more: xiahepublishing.com/2771-165…
👥 @CAPA_comm @gcai1978 @BreastCaupdates @ElisaAgostinett
UPDATE ALERT‼️
Read!👇
Great news‼️🚨 Updates to germline testing in #breastcancer patients from @ASCO and the Society of Surgical Oncology emphasize the paramount importance of BRCA1/2 mutation testing in newly diagnosed breast cancer patients, especially those ≤65 years of age, and in patients over 65 years of age, taking into account their personal history, relatives, ancestry, and eligibility for poly(ADP-ribose) polymerase inhibitor (PARP) therapy.
Recommendations:
🔵All newly diagnosed breast cancer patients ≤65 years of age should undergo BRCA1/2 mutation testing.
🟣Selected patients over 65 years of age should be evaluated based on history, ancestry, and eligibility for PARP therapy.
🟡Patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should undergo the BRCA1/2 test, regardless of family history.
🟠Women with second primary cancer in the ipsilateral or contralateral breast should undergo BRCA1/2 testing.
🟢Patients with a history of breast cancer, without active disease, should be evaluated, selectively, according to age of diagnosis and personal and family risk.
🌟Expansion of testing to high-penetrance cancer susceptibility genes beyond BRCA1/2 is also recommended, especially in those with a supportive family history. Where necessary, moderate-penetrance gene testing may be offered to assess personal and family cancer risk, this comprehensive approach makes a huge difference in personalizing breast cancer therapy and prevention.🙌🏻 @OncoReporte @oncosurgeonjd @Dr_RShatsky @ProfAMThompson
ascopubs.org/doi/full/10.120…
Breast Cancer Research Updates retweeted
New @JCO_ASCO🗞️| RCT of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With #BreastCancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study.
@tarasanftmd #JenniferLigibel @DrDawnHershman
👉pubmed.ncbi.nlm.nih.gov/3765…
Breast Cancer Research Updates retweeted
🚨After Neoadj chemo for cT1-2N0-1M0 TNBC or HER2+ BC, this trial used core biopsy to confirm pCR. Pts were then tx w/ RT alone WITHOUT breast surgery
Biopsy=pCR in 31/50 patients
‼️3-year ipsilateral breast tumour recurrence (IBTR) rate = 0% and 3-yr DFS and OS =100% #ESMO23 – at Madrid, Spain
Breast Cancer Research Updates retweeted
BEGONIA: Dato-DXd + Durvalumab in mTNBC update
ORR 79%
mPFS 13.8 mo
>80% with low PDL1 expression (by SP263 or 22C3)
Can IO lead to benefit even in PDL1- tumors when combined with a potent ADC?
#ESMO23 @OncoAlert #bcsm
UPDATE ‼️
TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo
63% w/1L prior chemo
~80% w/prior cdk 4/6i
PFS 6.9 vs 4.9 mo, HR 0.63, p<0.0001
ORR 36.4% vs 22.9%
Fewer grade >=3 AEs w/Dato-DXd c/w TPC
50% Stomatitis,3% ILD
@OncoAlert #bcsm #ESMO23 @dradityabardia
Breast Cancer Research Updates retweeted
⭐️Dr. Paolo Tarantino discusses the large improvement in pathological complete response w/chemo immunotherapy for high risk HR+ Stage 2/3 breast cancer. We also talk about the use of CDK4 inhibitor and PD inhibitor after surgery. #ESMO23 @CParkMD #OncLiveTakeOver
@PTarantinoMD – at Madrid, Spain
UPDATE - OBESITY & BREAST CANCER RECURRENCE‼️
This study suggests that obesity is associated with an increased risk of recurrence among patients with hormone receptor–positive breast cancer treated with aromatase inhibitors‼️
jamanetwork.com/journals/jam…
UPDATE‼️
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial | Journal of Clinical Oncology ‼️ ascopubs.org/doi/full/10.120…
Breast Cancer Research Updates retweeted
Healio spoke with @AnnPartridgeMD in this exclusive cover story regarding data that shows the overwhelming majority of new breast cancer diagnoses for women occur after the age of 40. Therefore, younger woman are underrepresented in clinical trials.
bit.ly/3Zt8y5T
Drug repurposing is great. The results from the MA.32 trial should discourage further investigation of metformin as an addition to adjuvant treatment of breast cancer patients…🛑
#bcsm
Another study showing metformin doesn't have the effect on improving risk or outcome for #bcsm that we hoped it might.
@ASCO
#MA32
ascopost.com/news/september-…
Breast Cancer Research Updates retweeted
The longest follow up to date of a metastatic trastuzumab trial: after 20 years from receiving TCH, 10% of the patients included in this phase 2 study was still alive. academic.oup.com/oncolo/adva…
How to recognize & increase the rate of long-term survivors? 👉 jamanetwork.com/journals/jam…
Breast Cancer Research Updates retweeted
Mark your calendar to join this #BCSM #TumorBoardTuesday 👆🏽
@DrSGraff @matteolambe @itrisabel @dr_yakupergun @NagiSaghir @YAbdouMD @BiagioRicciutMD @maryam_lustberg @DrEricWiner @AnselmoBertetti @anelcabrera @dsmithgraz @stolaney1 @DenizCanGuven1 @dralanreyesonco @HaanenJohn @ErikaHamilton9 @JAMouabbi @MartaPerachino @FuenteApolo @breastDoktor @amybeumer @oncologician @AnisToumeh @Icro_Meattini @DrJuliaKennedy1 @benjiwal @EMariamidze @GlopesMd @Dr_Ivanoncologo @WinshipAtEmory @OhioStateMedOnc
Breast Cancer Research Updates retweeted
🍂@jane_meisel @quirogad are finalizing the upcoming #BCSM #TumorBoardTuesday for 10/03
🌴Join at 8pm ET to discuss CDK4/6i treatment options & breaking updates to ADC use in those with HR+/HER2- met #BreastCancer
🏝️FREE #CME
👉🏽integrityce.com/TBT2023👈🏼
ALT #TumorBoardTuesday, Tuesday, October 3, 2023 8:00 PM - 9:00 PM ET @TumorBoardTues Jane L. Meisel, MD Dionisia Quiroga, DO, PhD CME credit available after participation. CME information: integrityce.com/tbt2023
Yeees❗️
Put this in your calendar 📅
Make sure to keep yourself updated‼️
Expect a great discussion and update on HR+ breast cancer 🧬🧬
@matteolambe @dr_yakupergun @ErikaHamilton9 @quirogad @BreastCaupdates @oncodaily @BreastAdvocate @Erman_Akkus
UPDATE FROM MA.32 trial ‼️
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10.120…
UPDATE ‼️
Future of breast cancer screening ⁉️
#bcsm
One radiologist supported by #AI detected more #breastcancer cases in screening #mammography than two radiologists working together, according to a study in @LancetDigitalH .
news.ki.se/more-cases-of-bre…
